SCHEMBL10243759

SCHEMBL10243759

COC(=O)NCCNC(C)c1ccc(OCC(=O)N(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
ACACB O00763 8/20 0.45
RAB9A P51151 1/20 0.42
TP53 P04637 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KEAP1 Q14145 2/20 0.38
NFE2L2 Q16236 2/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
ACACA Q13085 1/20 0.38
POLB P06746 1/20 0.38
TSHR P16473 1/20 0.37
OXTR P30559 1/20 0.37
SRD5A2 P31213 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10244841 0.88 TRPM8 (0.48) ACACBRAB9ATRPM8OXTR
SCHEMBL335399 0.84 SMN1; SMN2 (0.49) SMN1; SMN2ACACBRAB9ATP53ALDH1A1
SCHEMBL10243724 0.79 KMT2A (0.44) SMN1; SMN2ACACBRAB9AALDH1A1HPGD
SCHEMBL10244480 0.79 CYP1A2 (0.43) SMN1; SMN2ACACBRAB9ATP53ALDH1A1
SCHEMBL10245484 0.79 ALDH1A1 (0.53) RAB9AALDH1A1KDM4EHPGDPOLB
SCHEMBL10244285 0.77 ESR1 (0.42) SMN1; SMN2ACACBALDH1A1
SCHEMBL10243876 0.77 FKBP1A (0.65) SMN1; SMN2RAB9ATP53ALDH1A1KDM4E
SCHEMBL25017266 0.75 SMN1; SMN2 (0.61) SMN1; SMN2RAB9ATP53ALDH1A1KDM4E
SCHEMBL10243646 0.73 EPHX2 (0.41) SMN1; SMN2TSHR
SCHEMBL10243978 0.72 ALDH1A1 (0.51) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 SMN1; SMN2 3120/4885ACACB 4596/4885RAB9A 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.